NCT01810692 - Preference Tiotropium Respimat Study in COPD | Biotech Hunter

Enrollment

150

Participants

Timeline

Start Date

March 31, 2013

Primary Completion Date

March 31, 2014

Study Completion Date

March 31, 2014

Conditions

Pulmonary Disease, Chronic Obstructive

Interventions

DEVICE

Group1:Spiriva® Respimat®

COPD patients using Respimat®

DEVICE

Group2:Hirobriz®/Oslif®/Onbrez® Breezhaler®

COPD patients using Breezhaler®®

Trial Locations (15)

Boehringer Ingelheim Investigational Site 13, A Coruña

Boehringer Ingelheim Investigational Site 5, Barcelona

Boehringer Ingelheim Investigational Site 6, Barcelona

Boehringer Ingelheim Investigational Site 8, Barcelona

Boehringer Ingelheim Investigational Site 12, Burgos

Boehringer Ingelheim Investigational Site 14, Galdako.

Boehringer Ingelheim Investigational Site 11, Laredo

Boehringer Ingelheim Investigational Site 1, Málaga

Boehringer Ingelheim Investigational Site 3, Mérida

Boehringer Ingelheim Investigational Site 15, Palma de Mallorca

Boehringer Ingelheim Investigational Site 9, Pozuelo de Alarcón

Boehringer Ingelheim Investigational Site 7, Sabadell

Boehringer Ingelheim Investigational Site 2, Seville

Boehringer Ingelheim Investigational Site 10, Torrelodones

Boehringer Ingelheim Investigational Site 4, Villanueva de la Serena